Abstracts Poster Abstracts - Dr Falk

More documents

Recommendations

Info

Tumor stasis was achieved at clinically relevant doses of L19-IL2, whereas animalstreated with non-targeted IL2 showed only minor or no signs of therapeutic efficacy.Conclusion:These preclinical results support the ongoing clinical investigations of ZK 304709 andinitiation of clinical studies with L19-IL2 in solid cancer indications with high medicalneed including pancreatic and hepatocellular cancer.41
Special Lecture IVHow does pancreatic cancer develop?R.M. SchmidII. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München,GermanyPancreatic cancer is one of the most common causes of cancer related death.Despite the advances of the molecular pathogenesis, pancreatic cancer remains amajor unsolved health problem. Still, the 5-year survival rate is below 5% and of the10% of patients with respectable disease only around one fifth survive 5 years.Current therapeutic approaches have no impact in respect to overall survival.Cancer develops through stepwise accumulation of genetic alterations. Althoughsimilar genetic changes can be detected in specimens of different tumors, the type ofmutations, the sequence and the frequency of these alterations depends on thetumor type. Colon carcinogenesis has for years served as a model disease for themulti-step model of cancer. Lately a multi-step model for pancreatic carcinogenesishas been evolved and put foreward by Ralph Hruben and coworkers. Pancreaticintraepithelial neoplasia (PanIN 1 to 3) has been identified as precursor lesions. It isbelieved that genetic and epigenetic mechanisms work together to overcome intrinsictumor suppression during tumorigenesis. The structural alterations involve mutationsof the proto-oncogene KRAS and the tumor suppressors CDKN2A, TP53, BRCA2and SMAD4/DPC4 at different stages. The epigenetic changes are less wellcharacterized and include promotor methylation of genes controlling cell cycleprogression. Pancreatic cancer has some feature which distinguish it from othercancers. Pancreatic cancer is very aggressive and highly infiltrative. Even smalltumors metastasize to lymph nodes and perineually. The molecular mechanismsresponsible for this aggressiveness are so far unknown. Pancreatic tumor cellsdisplay a ductal differentiation although the cellular origin of pancreatic cancer isunknown. Recent studies using genetically defined mouse models resembling thehuman disease suggest that stem cells rather than terminally differentiated duct cellare the origin of tumor development. Treamtent of pancreatic cancer remains difficult.Recent clinical trails using "modern drugs" including antibodies and small moleculeswhich target signaling molecules shown to be important for pancreatic cancer biologyare disappointing. Therefore the development of new strategies to prevent pancreaticcance will be important in the future.42
Page 1 and 2: BERLINAbstractsPoster AbstractsGAST
Page 3 and 4: CONTENTSpageCholelithiasis and bili
Page 5 and 6: Session Liver IDiagnosis and survei
Page 7 and 8: Poster Abstracts1. Autoimmune pancr
Page 9 and 10: 24. Liver vascular index in NASH, c
Page 11 and 12: 47. Expression of claudins in human
Page 13 and 14: 67. Prevalence and association with
Page 15 and 16: 90. Ursofalk ® in cholestatic live
Page 17 and 18: 112. Agrin accumulates in the liver
Page 19: Molecular mechanisms controlling bi
Page 22 and 23: Etiology and pathogenesis of biliar
Page 25 and 26: Special Lecture IFuture development
Page 27 and 28: Pancreatic carcinoma
Page 29 and 30: 3. One pancreatic cancer case with
Page 31 and 32: However, the Melanoma Genetics Cons
Page 33 and 34: the pancreas encouraging duodenum p
Page 35 and 36: Pancreatic cancer: Surgery, palliat
Page 37: Special Lecture IIIDevelopment comp
Page 41 and 42: Session Liver IDiagnosis and survei
Page 43 and 44: Imaging modalitiesProf. Riccardo Le
Page 45 and 46: Session Liver IIMetabolic liver dis
Page 47 and 48: The role of insulin resistance and
Page 49 and 50: other adipocyte-derived factors, in
Page 51 and 52: Hereditary hemochromatosis: The gen
Page 53 and 54: Wilson disease: The impact of molec
Page 55 and 56: Immune pathogenesis of hepatitis B
Page 57 and 58: However, neither WHV DNA nor WHsAg
Page 59 and 60: The well established antiviral ther
Page 61 and 62: Genomics of hepatocellular carcinom
Page 63 and 64: A prospective study of more than 22
Page 65 and 66: treatment approach with HDACi toget
Page 67 and 68: statistically significant differenc
Page 69 and 70: Prof. Dr. H. FriessAllgemein-/Visze
Page 71 and 72: Prof. Dr. W.E. SchmidtInnere Medizi
Page 73 and 74: Autoimmune pancreatitis: An underdi
Page 75 and 76: Non-invasive parameters for predict
Page 77 and 78: Table 1Agegroups1986-1991m-w1992-19
Page 79 and 80: NTCP-mediated bile acid transport i
Page 81 and 82: 8The use of Ursofalk ® in patients
Page 83 and 84: 10High expression of agrin in hepat
Page 85 and 86: 12Chronic liver diseases associated
Page 87 and 88: 14Determination of hepatitis Delta
Page 89 and 90:
16Different expressions of claudins
Page 91 and 92:
For most of the morphological, hist
Page 93 and 94:
19Clinical and diagnostic value of
Page 95 and 96:
The impact of steatosis in fibrosis
Page 97 and 98:
23Unusual association between liver
Page 99 and 100:
25Effect of molsidomine and sin-1 o
Page 101 and 102:
27Concentration of antioxidative vi
Page 103 and 104:
29An assessment of cardiovascular m
Page 105 and 106:
Conclusions:1. Hepatic stellate cel
Page 107 and 108:
32Heme oxygenase-1 over-expression
Page 109 and 110:
34Autoimmune processes and alpha-in
Page 111 and 112:
36Therapy in non-alcoholic steatohe
Page 113 and 114:
38A case of hepatocellular carcinom
Page 115 and 116:
40Antigen-presenting cells in small
Page 117 and 118:
42Spatial complexity analysis of th
Page 119 and 120:
Endocrine cells in the large bile d
Page 121 and 122:
46Clinical features associated with
Page 123 and 124:
48Effect of losartan on early liver
Page 125:
50Assessment of histological featur
Page 128 and 129:
53Non-alcoholic fatty liver disease
Page 130 and 131:
55Helicobacter pylori infection and
Page 132 and 133:
57Mild to moderate autonomic dysfun
Page 134 and 135:
58Level of some proinflammatory cyt
Page 136 and 137:
60Port-site metastasis after laparo
Page 138 and 139:
62The influence of active prophylax
Page 140 and 141:
63Progressive familiar intrahepatic
Page 142 and 143:
65The survival rate among the Slova
Page 144 and 145:
66ILEI, a novel key component and r
Page 146 and 147:
68Clinical and pathological signifi
Page 148 and 149:
70High expression of claudin-7 duri
Page 150 and 151:
72Microhemorrheological disturbance
Page 152 and 153:
74High level of vitamin C in rat li
Page 154 and 155:
76Epidemiological analysis of HBV,
Page 156 and 157:
78Evaluation of Ursofalk ® 's effe
Page 158 and 159:
80Is the corticotherapy of malignan
Page 160 and 161:
82Transdifferentiation of hepatocyt
Page 162 and 163:
84The study of risk groups for chol
Page 164 and 165:
86Thrombocytosis as a prognostic fa
Page 166 and 167:
88Assessment of Helicobacter genus
Page 168 and 169:
90Ursofalk ® in cholestatic liver
Page 170 and 171:
92Activated hepatic stellate cells
Page 172 and 173:
94What is the actual prevalence of
Page 174 and 175:
96Hepatectomy for huge HCCJing-An R
Page 176 and 177:
98Increased expression of geranylge
Page 178 and 179:
100Helicobacter pylori eradication
Page 180 and 181:
102Treatment of pediatric metabolic
Page 182 and 183:
103A 5-years single center experien
Page 184 and 185:
104Tissue factor expression in inte
Page 186 and 187:
106Expression of matrilin-2 in live
Page 188 and 189:
108The significance of immunohistoc
Page 190 and 191:
110Hepatocellular carcinoma in pati
Page 192 and 193:
112Agrin accumulates in the liver d
Page 194 and 195:
114Prophylaxis of encephalopathy in
Page 196 and 197:
115Metadoxine modifies both apoptot
Page 198 and 199:
117Expression of the xenobiotic- an
Page 200 and 201:
Discussion/Conclusion: Compared wit
Page 202 and 203:
120Functional and morphological inj
Page 204 and 205:
Author Index to Poster Abstracts(Na
Page 206 and 207:
Guizzetti, M. 102Gulubova, M.V. 44,
Page 208 and 209:
Pascu, O. 94Páska, C. 10, 47, 106P
show all

Abstracts Poster Abstracts - Dr Falk

Create successful ePaper yourself

Delete template?

Save as template?